吉西他滨联合长春瑞滨治疗蒽环类和紫杉类耐药的晚期乳腺癌近期疗效观察

Recent Efficacy and Safety of Gemcitabine and Vinorelbine Combination Chemotherapy for Patients with Anthracycline and Taxane-Resistant Metastatic Breast Cancer

目的观察吉西他滨联合长春瑞滨方案治疗蒽环类和紫杉类均耐药的晚期乳腺癌的近期临床疗效和不良反应。方法吉西他滨联合长春瑞滨治疗蒽环类和紫杉类均耐药的晚期乳腺癌患者29例,21～28 d为1个周期,至少连续2周期化疗后评价临床疗效和不良反应。结果完全缓解0例、部分缓解11例、稳定12例、进展6例;有效率37.9%,临床获益率55.2%;主要不良反应为骨髓抑制及胃肠道反应。结论吉西他滨联合长春瑞滨方案治疗蒽环类和紫杉类均耐药的晚期乳腺癌有较好的疗效,不良反应可耐受,可考虑作为解救方案。

Objective To evaluate recent efficacy and safety of gemcitabine and vinorelbine combination chemotherapy for patients with anthraeycline and taxane-resistant metastatic breast cancer. Methods Twenty nine patients with anthracycline and taxane-resistant metastatic breast cancer were treated with gemcitabine combined with vinorelbine,21 -28 days for a cycle;the response was assessed after the second cycle. Results Among 29 patients, there were 0 case CR（ complete response）, 11 PR（ partial response）, 12 SD（ stable disease） ,6 PD（ progress disease）. The overall response rate（ RR = CR ＋ PR） was 37.9%, clinical benefit rate（ CR ＋ PR ＋ SD） was 55.2%. The main toxicity was myelosuppression and gastrointestinal reactions. Conclusion Gemcitabine combined with vinorelbine is active in the treatment of anthracycline and taxane-resistant metastatic breast cancer with acceptable toxicity, and may be an effective salvage therapy.